Interius BioTherapeutics / Kite-Gilead
Interius develops targeted lentiviral in vivo CAR therapies. Its clinical lead INT2104 targets CD20 and engineers T and NK cells. Gilead’s annual filing confirms that the acquisition closed in October 2025; Interius is a wholly owned subsidiary.
Corporate information
- Company entity
- Interius BioTherapeutics / Kite-Gilead
- Headquarters / principal office
- No verified public location identified
- Founded
- 2019 ↗
- Ownership / capital status
- AcquiredNot verified
- Official corporate reference
- https://www.interiusbio.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Interius develops targeted lentiviral in vivo CAR therapies. Its clinical lead INT2104 targets CD20 and engineers T and NK cells. Gilead’s annual filing confirms that the acquisition closed in October 2025; Interius is a wholly owned subsidiary.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Primary corporate profile / legal-entity disclosure
- Interius BioTherapeutics / Kite-Gilead — supporting primary disclosure
- Founding / incorporation disclosure — scope stated in field